Генетическая карта здоровья (стр. 8 )

69. Matok, I., et al., Exposure To Folic Acid Antagonists During The First Trimester of Pregnancy and the Risk of Major Malformations. British Journal of Clinical Pharmacology, 2009. 68(6): p. 956-62.

70. Boccia, S., et al., Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. Cancer Lett, 2008.

71. Stidley, C. A., et al., Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Res, 2010. 70(2): p. 568-74.

72. Beetstra, S., et al., Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer. Cancer Epidemiol Biomarkers Prev, 2008. 17(10): p. 2565-71.

73. Boccia, S., et al., Meta - and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review. Am J Epidemiol, 2008. 167(5): p. 505-16.

74. Cushman, M., The role of imflammation in Cardiovascular disease and effect of hormon replasment, in Материалы V международного симпозиума по проблемам здоровья женщин и менопаузе. 2004: Италия.

75. Макацария, А. Д., , and , Профилактика и лечение тромбоэмболических осложнений в акушерстве, in Тромбозы и тромбоэмболии в акушерско-гинекологической клинике. 2007, Медицинское информационное агенство: М. p. 1064.

76. Deloughery, T. G., et al., Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation, 1996. 94(12): p. 3074-8.

77. Malinow, M. R., et al., The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol, 1997. 17(6): p. 1157-62.

78. Laraqui, A., et al., Influence of methionine synthase (A2756G) and methionine synthase reductase (A66G) polymorphisms on plasma homocysteine levels and relation to risk of coronary artery disease. Acta Cardiol, 2006. 61(1): p. 51-61.

79. Furness, D. L., et al., One-carbon metabolism enzyme polymorphisms and uteroplacental insufficiency. Am J Obstet Gynecol, 2008. 199(3): p. 276 e1-8.

80. Barbosa, P. R., et al., Association between decreased vitamin levels and MTHFR, MTR and MTRR gene polymorphisms as determinants for elevated total homocysteine concentrations in pregnant women. Eur J Clin Nutr, 2008. 62(8): p. 1010-21.

81. Wilson, A., et al., A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab, 1999. 67(4): p. 317-23.

82. Zhu, H., et al., Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab, 2003. 78(3): p. 216-21.

83. Varga, E. A., B. A. Kerlin, and M. W. Wurster, Social and ethical controversies in thrombophilia testing and update on genetic risk factors for venous thromboembolism. Semin Thromb Hemost, 2008. 34(6): p. 549-61.

84. Haverkate, F. and M. Samama, Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost, 1995. 73(1): p. 151-61.

85. van 't Hooft, F. M., et al., Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol, 1999. 19(12): p. 3063-70.

86. Humphries, S. E., J. A. Henry, and H. E. Montgomery, Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coagul Fibrinolysis, 1999. 10 Suppl 1: p. S17-21.

87. Bots, M. L., et al., Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health, 2002. 56 Suppl 1: p. i14-8.

88. Sampaio, M. F., et al., AMI is associated with polymorphisms in the NOS3 and FGB but not in PAI-1 genes in young adults. Clin Chim Acta, 2007. 377(1-2): p. 154-62.

89. Martiskainen, M., et al., Fibrinogen gene promoter -455 A allele as a risk factor for lacunar stroke. Stroke, 2003. 34(4): p. 886-91.

90. Martinelli, N., et al., Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis. PLoS ONE, 2008. 3(2): p. e1523.

91. Scarabin, P. Y., et al., Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb, 1993. 13(6): p. 886-91.

92. Panahloo, A., et al., Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes, 1995. 44(1): p. 37-42.

93. Simpson, A. J., et al., The effects of chronic smoking on the fibrinolytic potential of plasma and platelets. Br J Haematol, 1997. 97(1): p. 208-13.

94. Kruithof, E. K., Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost, 2008. 100(6): p. 969-75.

95. Kohler, H. P. and P. J. Grant, Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med, 2000. 342(24): p. 1792-801.

96. Carmeliet, P., et al., Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation, 1997. 96(9): p. 3180-91.

97. Wiklund, P. G., et al., Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke, 2005. 36(8): p. 1661-5.

98. Balta, G., C. Altay, and A. Gurgey, PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol, 2002. 71(2): p. 89-93.

99. Vergouwen, M. D., et al., Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke, 2004. 35(6): p. 1280-3.

100. Yamada, N., et al., The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet, 2000. 45(3): p. 138-41.

101. Cho, S. H., C. H. Ryu, and C. K. Oh, Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Exp Biol Med (Maywood), 2004. 229(2): p. 138-46.

102. Buckova, D., L. Izakovicova Holla, and J. Vacha, Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy, 2002. 57(5): p. 446-8.

103. Kowal, K., et al., Analysis of -675 4G/5G SERPINE1 and C-159T CD14 polymorphisms in house dust mite-allergic asthma patients. J Investig Allergol Clin Immunol, 2008. 18(4): p. 284-92.

104. Moshfegh, K., et al., Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet, 1999. 353(9150): p. 351-4.

105. Tsantes, A. E., et al., Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: a meta-analysis. Int J Cardiol, 2007. 118(2): p. 189-96.

106. Nikolopoulos, G. K., et al., Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: a meta-analysis. Thromb Res, 2007. 119(4): p. 501-10.

, G., Z. Wang, and Y. Ding, Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J Huazhong Univ Sci Technolog Med Sci, 2007. 27(6): p. 664-7.

108. Maeno, T., et al., The 807T allele in alpha2 integrin is protective against atherosclerotic arterial wall thickening and the occurrence of plaque in patients with type 2 diabetes. Diabetes, 2002. 51(5): p. 1523-8.

109. Kishimoto, T., The biology of interleukin-6. Blood, 1989. 74(1): p. 1-10.

110. Kita, M., et al., Induction of cytokines in human peripheral blood mononuclear cells by mycoplasmas. Microbiol Immunol, 1992. 36(5): p. 507-16.

111. Mysliwska, J., et al., The -174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus. Pediatr Res, 2009. 66(3): p. 341-5.

112. Tischendorf, J. J., et al., The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. Int J Immunogenet, 2007. 34(6): p. 413-8.

113. Kamarainen, O. P., et al., Common interleukin-6 promoter variants associate with the more severe forms of distal interphalangeal osteoarthritis. Arthritis Res Ther, 2008. 10(1): p. R21.

114. Naumova, E., et al., Immunological markers contributing to successful aging in Bulgarians. Exp Gerontol, 2004. 39(4): p. 637-44.

115. Treszl, A., et al., Genetic variants of TNF-[FC12]a, IL-1beta, IL-4 receptor [FC12]a-chain, IL-6 and IL-10 genes are not risk factors for sepsis in low-birth-weight infants. Biol Neonate, 2003. 83(4): p. 241-5.

116. Schaaf, B. M., et al., Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med, 2003. 168(4): p. 476-80.

117. Moscovis, S. M., et al., Interleukin-10 and sudden infant death syndrome. FEMS Immunol Med Microbiol, 2004. 42(1): p. 130-8.

118. Zedan, M., et al., Gene polymorphisms of tumor necrosis factor alpha-308 and interleukin-10-1082 among asthmatic Egyptian children. Allergy Asthma Proc, 2008. 29(3): p. 268-73.

119. Karjalainen, J., et al., Interleukin-10 gene promoter region polymorphism is associated with eosinophil count and circulating immunoglobulin E in adult asthma. Clin Exp Allergy, 2003. 33(1): p. 78-83.

120. Hakansson, A., et al., Investigation of genes coding for inflammatory components in Parkinson's disease. Mov Disord, 2005. 20(5): p. 569-73.

121. Fernandez, L., et al., Interleukin-10 polymorphisms in Spanish patients with IBD. Inflamm Bowel Dis, 2005. 11(8): p. 739-43.

122. Bantis, C., et al., Association of interleukin-10 gene G-1082A polymorphism with the progression of primary glomerulonephritis. Kidney Int, 2004. 66(1): p. 288-94.

123. Flanagan, S. E., et al., Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes, 2007. 56(7): p. 1930-7.

124. Stancakova, A., et al., Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes, 2009. 58(9): p. 2129-36.

125. Tabara, Y., et al., Replication study of candidate genes associated with type 2 diabetes based on genome-wide screening. Diabetes, 2009. 58(2): p. 493-8.

126. van Dam, R. M., et al., Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses. Diabet Med, 2005. 22(5): p. 590-8.

127. Yokoi, N., et al., Association studies of variants in the genes involved in pancreatic beta-cell function in type 2 diabetes in Japanese subjects. Diabetes, 2006. 55(8): p. 2379-86.

128. Zhou, D., et al., The E23K variation in the KCNJ11 gene is associated with type 2 diabetes in Chinese and East Asian population. J Hum Genet, 2009. 54(7): p. 433-5.

129. Reyes, S., et al., K(ATP) channel Kir6.2 E23K variant overrepresented in human heart failure is associated with impaired exercise stress response. Hum Genet, 2009.

130. Lyssenko, V., et al., Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest, 2007. 117(8): p. 2155-63.

131. Pilgaard, K., et al., The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia, 2009.

132. Helgason, A., et al., Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet, 2007. 39(2): p. 218-25.

133. Tong, Y., et al., Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet, 2009. 10: p. 15.

134. Florez, J. C., et al., TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med, 2006. 355(3): p. 241-50.

135. Romagnani, S., Human TH1 and TH2 subsets: doubt no more. Immunol Today, 1991. 12(8): p. 256-7.

136. Zhu, S., et al., Polymorphisms of the IL-4, TNF-alpha, and Fcepsilon RIbeta genes and the risk of allergic disorders in at-risk infants. Am J Respir Crit Care Med, 2000. 161(5): p. 1655-9.

137. Li, Y., et al., Association between C-589T polymorphisms of interleukin-4 gene promoter and asthma: a meta-analysis. Respir Med, 2008. 102(7): p. 984-92.

138. Sandford, A. J., et al., Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol, 2000. 106(1 Pt 1): p. 135-40.

139. Gervaziev, Y. V., V. A. Kaznacheev, and V. B. Gervazieva, Allelic polymorphisms in the interleukin-4 promoter regions and their association with bronchial asthma among the Russian population. Int Arch Allergy Immunol, 2006. 141(3): p. 257-64.

[1] - поскольку ген AGTR2 расположен на X хромосоме, то у мужчин имеется только один аллель и, формально, гомозиготный генотип должен обозначаться как G/- или A/-, но для удобства используется привычное обозначение гомозигот G/G и A/A.